<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004312</url>
  </required_header>
  <id_info>
    <org_study_id>2019-4650</org_study_id>
    <nct_id>NCT04004312</nct_id>
  </id_info>
  <brief_title>Single Fractions SBRT for Prostate Cancer</brief_title>
  <official_title>Single Fractions SBRT in the Treatment of Prostate Cancer: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fabio Cury</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in
      patients with low- and favorable intermediate-risk prostate cancer that will undergo
      placement of the SpaceOAR hydrogel prior to treatment.

      Our hypothesis is that treatments can be safely delivered in one single fraction using SBRT
      provided the separation between the prostate and rectum is increased using the hydrogel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a pre-treatment visit to the radiation oncology department. A gel is injected
      between the prostate and the rectum. This procedure is done with the use of a transrectal
      ultrasound, similarly to the prostate biopsy the patient had. A local anesthetic will be
      applied to numb the skin and to the underneath tissue where the injection will be performed.
      The procedure itself will take approximately 20 minutes and after a short observation time,
      the patient returns home.

      The next visit (approximately after 7 days after the insertion of the gel), a CT scan and
      MRI-scan will be done. Prior to the scans, a urinary catheter will be inserted in the bladder
      through the penis, and removed once the scans are done. Using these images, the doctor and
      the team involved will perform an individualized planning study to establish the safest way
      the radiation will enter your body. When the treatment plan is ready, patient is called to
      receive the single treatment.

      A urinary catheter again will be inserted in the bladder and the patient will be directed to
      the room where your treatment will be delivered. The treatment should last approximately 30
      minutes. After the treatment, the urinary catheter will be removed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Small bowel or rectal irritation,</measure>
    <time_frame>3 months</time_frame>
    <description>To assess acute gastro-intestinal (GI) toxicity such as abdominal cramping, diarrhea, rectal urgency, proctitis, or hematochezia;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder complications</measure>
    <time_frame>3 months</time_frame>
    <description>Bladder complications including urinary frequency/urgency, dysuria, hematuria, urinary tract infection, and incontinence;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess late GI and GU toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>gastro-intestinal (GI) toxicity such as abdominal cramping, diarrhea, rectal urgency, proctitis, or hematochezia;and GU toxicity such as Bladder complications including urinary frequency/urgency, dysuria, hematuria, urinary tract infection, and incontinence;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA control</measure>
    <time_frame>5 years</time_frame>
    <description>To assess the rate of biochemical control</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single Fraction SBRT in the treatment of prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.</description>
    <arm_group_label>Single Fraction SBRT in the treatment of prostate cancer</arm_group_label>
    <other_name>Space OAR Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically proven adenocarcinoma of the prostate. Tl-2b (AJCC 7th edition) Gleason
        score 6 or 7 (3+4)) or Gleason 7(4+3) and recent PSA &lt; 10 (less than 30 days; must obtained
        &gt;90 days from stopping dutasteride or &gt;30 days from stopping finasteride)

        Recent PSA under 15 ng/dL (less than 30 days; must obtained &gt;90 days from stopping
        dutasteride or &gt;30 days from stopping finasteride) OR Gleason 7(4+3) and recent PSA &lt; 10
        (less than 30 days; must obtained &gt;90 days from stopping dutasteride or &gt;30 days from
        stopping finasteride)

        International Prostate Symptom Score &lt;16 Prostate gland volume&lt; 80cc

        Zubrod Performance Status 0-1 within 60 days prior to registration

        Age &gt;: 18

        Patient must be able to provide study-specific informed consent prior to study entry.

        Exclusion Criteria:

        Patients who opt to receive another treatment modality, such as surgery, or undergo active
        surveillance.

        Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or
        lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5
        years. All patients with in situ carcinoma are eligible for this study (for example,
        carcinoma in situ of the oral cavity) except patients with carcinoma of the bladder
        (including in situ bladder cancer or superficial bladder cancer).

        Evidence of distant metastases

        Regional lymph node involvement

        Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer Previous
        pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy Previous hormonal
        therapy, such as LHRH agonists or antagonists, anti-androgens, estrogens, or surgical
        castration (orchiectomy)

        Use of finasteride within 30 days prior to registration. PSA should not be obtained prior
        to 30 days after stopping finasteride.

        Use of dutasteride within 90 days prior to registration. PSA should not be obtained prior
        to 90 days after stopping dutasteride.

        Previous or concurrent cytotoxic chemotherapy for prostate cancer Severe, active
        co-morbidity, defined as follows:

        Unstable angina and/or congestive heart failure requiring hospitalization within the last 6
        months

        Transmural myocardial infarction within the last 6 months

        Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
        registration

        Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring
        hospitalization or precluding study therapy at the time of registration

        Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note,
        however, that laboratory tests for liver function and coagulation parameters are not
        required for entry into this protocol. (Patients on Coumadin or other blood thinning agents
        are eligible for this study.)

        Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note,
        however, that HIV testing is not required for entry into this protocol. The need to exclude
        patients with AIDS from this protocol is necessary because the treatments involved in this
        protocol may be significantly immunosuppressive. Protocol-specific requirements may also
        exclude immuno-compromised patients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Cury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre- Cedars Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianna Perna</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>43191</phone_ext>
    <email>marianna.perna@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana Carvalho</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>43698</phone_ext>
    <email>tatiana.carvalho@muhc.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McGill University Health Centre-Cedars Cancer Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Perna</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43191</phone_ext>
      <email>marianna.perna@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Carvalho</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43698</phone_ext>
      <email>tatiana.carvalho@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio Cury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Souhami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Duclos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Faria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):213-4.</citation>
    <PMID>11516871</PMID>
  </reference>
  <reference>
    <citation>Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1093-104.</citation>
    <PMID>12829147</PMID>
  </reference>
  <reference>
    <citation>King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. doi: 10.1016/j.ijrobp.2010.11.054. Epub 2011 Feb 6.</citation>
    <PMID>21300474</PMID>
  </reference>
  <reference>
    <citation>Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010 Feb 1;10:1. doi: 10.1186/1471-2490-10-1.</citation>
    <PMID>20122161</PMID>
  </reference>
  <reference>
    <citation>Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97. doi: 10.1016/j.ijrobp.2007.11.067.</citation>
    <PMID>18374232</PMID>
  </reference>
  <reference>
    <citation>Faria S, Ruo R, Cury F, Duclos M, Souhami L. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. Pract Radiat Oncol. 2017 Jul - Aug;7(4):264-269. doi: 10.1016/j.prro.2017.01.003. Epub 2017 Jan 20.</citation>
    <PMID>28222995</PMID>
  </reference>
  <reference>
    <citation>Faria SL, Neto OB, Cury F, Shenouda G, Russel R, Souhami L. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. Can J Urol. 2016 Apr;23(2):8209-14.</citation>
    <PMID>27085825</PMID>
  </reference>
  <reference>
    <citation>Patel N, Faria S, Cury F, David M, Duclos M, Shenouda G, Ruo R, Souhami L. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):534-9. doi: 10.1016/j.ijrobp.2013.02.010. Epub 2013 Apr 15.</citation>
    <PMID>23597418</PMID>
  </reference>
  <reference>
    <citation>Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L. Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):805-10. doi: 10.1016/j.ijrobp.2009.05.047.</citation>
    <PMID>20510194</PMID>
  </reference>
  <reference>
    <citation>Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.</citation>
    <PMID>28296582</PMID>
  </reference>
  <reference>
    <citation>Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448. Epub 2016 Apr 4.</citation>
    <PMID>27044935</PMID>
  </reference>
  <reference>
    <citation>Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.</citation>
    <PMID>27339115</PMID>
  </reference>
  <reference>
    <citation>Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008 Dec;20(10):729-37. doi: 10.1016/j.clon.2008.08.006. Epub 2008 Oct 5.</citation>
    <PMID>18838256</PMID>
  </reference>
  <reference>
    <citation>McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, Collins SP, Kaplan ID. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012 Aug 1;118(15):3681-90. doi: 10.1002/cncr.26699. Epub 2011 Dec 13.</citation>
    <PMID>22170628</PMID>
  </reference>
  <reference>
    <citation>Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105.</citation>
    <PMID>17336216</PMID>
  </reference>
  <reference>
    <citation>Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, Tang C, Quon H, Jain S, Pang G, Nam R. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013 May;107(2):153-8. doi: 10.1016/j.radonc.2013.03.022. Epub 2013 May 3.</citation>
    <PMID>23647750</PMID>
  </reference>
  <reference>
    <citation>Lin YW, Lin LC, Lin KL. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer. Front Oncol. 2014 Oct 31;4:278. doi: 10.3389/fonc.2014.00278. eCollection 2014.</citation>
    <PMID>25401085</PMID>
  </reference>
  <reference>
    <citation>Ju AW, Wang H, Oermann EK, Sherer BA, Uhm S, Chen VJ, Pendharkar AV, Hanscom HN, Kim JS, Lei S, Suy S, Lynch JH, Dritschilo A, Collins SP. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol. 2013 Jan 31;8:30. doi: 10.1186/1748-717X-8-30.</citation>
    <PMID>23369294</PMID>
  </reference>
  <reference>
    <citation>King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013 Nov;109(2):217-21. doi: 10.1016/j.radonc.2013.08.030. Epub 2013 Sep 20.</citation>
    <PMID>24060175</PMID>
  </reference>
  <reference>
    <citation>Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009 Oct;8(5):387-92.</citation>
    <PMID>19754215</PMID>
  </reference>
  <reference>
    <citation>Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.</citation>
    <PMID>23497695</PMID>
  </reference>
  <reference>
    <citation>Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat. 2010 Oct;9(5):473-7.</citation>
    <PMID>20815418</PMID>
  </reference>
  <reference>
    <citation>Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014 Sep 2;4:240. doi: 10.3389/fonc.2014.00240. eCollection 2014.</citation>
    <PMID>25229051</PMID>
  </reference>
  <reference>
    <citation>Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.</citation>
    <PMID>26798571</PMID>
  </reference>
  <reference>
    <citation>Katz A, Formenti SC, Kang J. Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure. Front Oncol. 2016 Jul 8;6:168. doi: 10.3389/fonc.2016.00168. eCollection 2016.</citation>
    <PMID>27458572</PMID>
  </reference>
  <reference>
    <citation>Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb;7(1):e43-e49. doi: 10.1016/j.prro.2016.06.010. Epub 2016 Jun 24.</citation>
    <PMID>27637137</PMID>
  </reference>
  <reference>
    <citation>Quon HC, Musunuru HB, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Zhang L, Loblaw A. Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials. Front Oncol. 2016 Aug 29;6:185. doi: 10.3389/fonc.2016.00185. eCollection 2016.</citation>
    <PMID>27622157</PMID>
  </reference>
  <reference>
    <citation>Avkshtol V, Dong Y, Hayes SB, Hallman MA, Price RA, Sobczak ML, Horwitz EM, Zaorsky NG. A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Res Rep Urol. 2016 Aug 18;8:145-58. doi: 10.2147/RRU.S58262. eCollection 2016. Review.</citation>
    <PMID>27574585</PMID>
  </reference>
  <reference>
    <citation>Prada PJ, Cardenal J, Blanco AG, Anchuelo J, Ferri M, Fernández G, Arrojo E, Vázquez A, Pacheco M, Fernández J. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results. Radiother Oncol. 2016 Jun;119(3):411-6. doi: 10.1016/j.radonc.2016.04.006. Epub 2016 Apr 22.</citation>
    <PMID>27118583</PMID>
  </reference>
  <reference>
    <citation>Jawad MS, Dilworth JT, Gustafson GS, Ye H, Wallace M, Martinez A, Chen PY, Krauss DJ. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):657-66. doi: 10.1016/j.ijrobp.2015.10.011. Epub 2015 Nov 10.</citation>
    <PMID>26797541</PMID>
  </reference>
  <reference>
    <citation>Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, Milner J, Cladd H. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1376-84. doi: 10.1016/j.ijrobp.2011.04.031. Epub 2011 Jun 15.</citation>
    <PMID>21680108</PMID>
  </reference>
  <reference>
    <citation>Ghilezan M, Martinez A, Gustason G, Krauss D, Antonucci JV, Chen P, Fontanesi J, Wallace M, Ye H, Casey A, Sebastian E, Kim L, Limbacher A. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):927-32. doi: 10.1016/j.ijrobp.2011.05.001. Epub 2011 Dec 23.</citation>
    <PMID>22197086</PMID>
  </reference>
  <reference>
    <citation>Morton G, Chung HT, McGuffin M, Helou J, D'Alimonte L, Ravi A, Cheung P, Szumacher E, Liu S, Al-Hanaqta M, Zhang L, Mamedov A, Loblaw A. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radiother Oncol. 2017 Jan;122(1):87-92. doi: 10.1016/j.radonc.2016.10.019. Epub 2016 Nov 4.</citation>
    <PMID>27823821</PMID>
  </reference>
  <reference>
    <citation>Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M 3rd, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21;11:8. doi: 10.1186/s13014-016-0585-y.</citation>
    <PMID>26792201</PMID>
  </reference>
  <reference>
    <citation>Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Daignault-Newton S, Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985. doi: 10.1016/j.ijrobp.2016.12.024. Epub 2016 Dec 23.</citation>
    <PMID>28209443</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Fabio Cury</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>single fraction</keyword>
  <keyword>SBRT</keyword>
  <keyword>Space OAR Gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

